ArticleDiscover oncology2026
Bibliometric insights into the advancements and future directions of hypofractionated radiotherapy in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRadiotherapy is essential after breast cancer surgery to prevent local recurrence. However, conventional fractionation involves extended treatment courses that can strain healthcare resources. In recent years, hypofractionated radiotherapy (HFRT), which delivers larger doses per session over a shorter overall period, has gained traction as a practical and effective alternative. This study employed bibliometric methods to explore the global research landscape and key focus areas in hypofractionated radiotherapy for breast cancer.
methodsTo map out how research in this area has developed, we carried out a bibliometric review of the existing literature. We examined 1,521 English-language studies published between 2005 and 2025, indexed in the Web of Science database. Using tools like Bibliometrix, VOSviewer, and CiteSpace, we tracked publication trends, knowledge frameworks, and collaborative networks over time.
resultsThe findings reveal a marked progressive increase in annual publications, with a pronounced upturn after 2020 culminating in a peak of 152 articles in 2021. The United States, Italy, and the United Kingdom contributed the most studies historically, though China has shown striking growth in recent years. The focus of research has shifted: early work centered on optimizing dose schedules, later moving toward assessing toxicity and validating outcomes through clinical trials. Recently, attention has turned to even shorter "ultra-hypofractionated" regimens. Current citation trends highlight toxicity profiling as a particularly active topic of investigation.
conclusionResearch on HFRT has evolved from establishing non-inferiority to conventional radiotherapy toward a growing focus on safety, precision, and individualized treatment. This study provides a data-driven overview of this evolution, which we hope will help steer future research and inspire further advances in hypofractionated radiotherapy for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.